AU2002365196C1 - Multimeric proteins and methods of making and using same - Google Patents

Multimeric proteins and methods of making and using same Download PDF

Info

Publication number
AU2002365196C1
AU2002365196C1 AU2002365196A AU2002365196A AU2002365196C1 AU 2002365196 C1 AU2002365196 C1 AU 2002365196C1 AU 2002365196 A AU2002365196 A AU 2002365196A AU 2002365196 A AU2002365196 A AU 2002365196A AU 2002365196 C1 AU2002365196 C1 AU 2002365196C1
Authority
AU
Australia
Prior art keywords
polypeptide
multimerization
multimeric protein
seq
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002365196A
Other languages
English (en)
Other versions
AU2002365196B8 (en
AU2002365196B2 (en
AU2002365196A1 (en
Inventor
Catherine Helen Charles
Fang Fang
Lori Allison Kohlstaedt
Guang-Xiang Luo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perlan Therapeutics Inc
Original Assignee
Perlan Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perlan Therapeutics Inc filed Critical Perlan Therapeutics Inc
Publication of AU2002365196A1 publication Critical patent/AU2002365196A1/en
Publication of AU2002365196B2 publication Critical patent/AU2002365196B2/en
Publication of AU2002365196B8 publication Critical patent/AU2002365196B8/en
Priority to AU2009201466A priority Critical patent/AU2009201466B2/en
Application granted granted Critical
Publication of AU2002365196C1 publication Critical patent/AU2002365196C1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
AU2002365196A 2001-07-19 2002-07-19 Multimeric proteins and methods of making and using same Ceased AU2002365196C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2009201466A AU2009201466B2 (en) 2001-07-19 2009-04-15 Multimeric proteins and methods of making and using same

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30674601P 2001-07-19 2001-07-19
US60/306,746 2001-07-19
US33542501P 2001-11-30 2001-11-30
US60/335,425 2001-11-30
PCT/US2002/023003 WO2003062370A2 (en) 2001-07-19 2002-07-19 Multimeric proteins and methods of making and using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2009201466A Division AU2009201466B2 (en) 2001-07-19 2009-04-15 Multimeric proteins and methods of making and using same

Publications (4)

Publication Number Publication Date
AU2002365196A1 AU2002365196A1 (en) 2003-09-18
AU2002365196B2 AU2002365196B2 (en) 2009-01-15
AU2002365196B8 AU2002365196B8 (en) 2009-01-29
AU2002365196C1 true AU2002365196C1 (en) 2009-08-13

Family

ID=27616555

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002365196A Ceased AU2002365196C1 (en) 2001-07-19 2002-07-19 Multimeric proteins and methods of making and using same
AU2009201466A Ceased AU2009201466B2 (en) 2001-07-19 2009-04-15 Multimeric proteins and methods of making and using same

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2009201466A Ceased AU2009201466B2 (en) 2001-07-19 2009-04-15 Multimeric proteins and methods of making and using same

Country Status (6)

Country Link
US (3) US20030138440A1 (https=)
EP (1) EP1578917A4 (https=)
JP (3) JP2005522192A (https=)
AU (2) AU2002365196C1 (https=)
CA (2) CA2454358A1 (https=)
WO (1) WO2003062370A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69829995T2 (de) * 1997-12-01 2006-02-23 Fang, Fang, San Diego Multivalente rekombinante antikörper zur behandlung von hrv infektionen
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
EP1578917A4 (en) 2001-07-19 2008-01-23 Perlan Therapeutics Inc MULTIMEDIA PROTEINS AND METHODS FOR THE PRODUCTION AND USE THEREOF
US8475789B2 (en) * 2008-01-22 2013-07-02 Multimerics Aps Products and methods to prevent infections
WO2009111304A2 (en) 2008-02-29 2009-09-11 President And Fellows Of Harvard College A fusion-intermediate state of hiv-1 gp41 targeted by broadly neutralizing antibodies
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
HUE047278T2 (hu) 2011-08-05 2020-04-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
WO2013078425A1 (en) * 2011-11-22 2013-05-30 University Of Maryland, Baltimore Lambodies with high affinity and selectivity for glycans and uses therefor
US10329350B2 (en) 2012-12-26 2019-06-25 Industrial Technology Research Institute Method for producing a multivalent fab fragment with collagen-like peptide
US20150038682A1 (en) * 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
US10561805B2 (en) * 2014-10-10 2020-02-18 Ablynx N.V. Methods of treating RSV infections
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
KR102682118B1 (ko) 2016-04-29 2024-07-08 주식회사유한양행 Ccl3 변이체를 포함하는 융합 단백질 및 이의 용도
JP2022522405A (ja) 2019-03-06 2022-04-19 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
EP3935079A4 (en) 2019-03-06 2023-03-22 Cue Biopharma, Inc. T-CELL MODULATING ANTIGEN PRESENT POLYPEPTIDES AND METHODS OF USE THEREOF
DK4034170T3 (da) 2019-10-23 2026-03-30 Cue Biopharma Inc Tgf-beta-polypeptider

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
FR2562421B1 (fr) 1984-04-09 1989-02-17 Sandoz Sa Perfectionnements a la therapie par l'interleukine
EP0169146A3 (en) 1984-07-20 1988-07-20 Merck & Co. Inc. Monoclonal antibodies directed against the cellular receptor of human rhinovirus
US4698420A (en) * 1985-02-25 1987-10-06 Xoma Corporation Antibody hybrid molecules and process for their preparation
US5077195A (en) * 1985-03-01 1991-12-31 Board Of Reagents, The University Of Texas System Polypeptides complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known and methods of design therefor
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
EP0225130B1 (en) 1985-11-22 1991-10-30 Takeda Chemical Industries, Ltd. Liposome composition
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US6121424A (en) 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
JP2666345B2 (ja) 1987-04-16 1997-10-22 武田薬品工業株式会社 リポソーム製剤およびその製造法
ES2080044T3 (es) 1987-05-04 1996-02-01 Dana Farber Cancer Inst Inc Moleculas de adhesion intercelular y sus ligandos de fijacion.
US5284931A (en) 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US5565550A (en) 1987-05-04 1996-10-15 Dana Farber Cancer Institute Antibodies to ICAM-2, and fragments thereof
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68929167T2 (de) 1988-09-06 2000-11-16 Xoma Corp., Berkeley Genexpressions-Elemente und Herstellung von chimären Maus-Mensch-Antikörpern
ES2201052T3 (es) 1988-09-28 2004-03-16 Dana Farber Cancer Institute Moleculas de adhesion intercelular y sus ligandos de union.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH04503306A (ja) 1989-02-01 1992-06-18 ザ・ジェネラル・ホスピタル・コーポレーション 単純ヘルペスウイルス１型発現ベクター
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
ES2035668T3 (es) 1989-03-09 1993-04-16 Boehringer Ingelheim Pharmaceuticals Inc. Uso de moleculas de adherencia intercelular y sus ligandos de union en el tratamiento del asma.
US5081584A (en) * 1989-03-13 1992-01-14 United States Of America Computer-assisted design of anti-peptides based on the amino acid sequence of a target peptide
EP0404003A3 (en) 1989-06-19 1991-10-16 Xoma Corporation Chimeric mouse-human km10 antibody with specificity to a human tumor cell antigen
US5324510A (en) 1989-09-01 1994-06-28 Boehringer Ingelheim Pharmaceuticals, Inc. Use of antibodies to intercellular adhesion molecule-1 (ICAM-1) in the treatment of asthma
EP0457875A4 (en) 1989-11-13 1993-03-03 Xoma Corporation Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
CA2044627A1 (en) 1989-11-13 1991-05-14 Randy R. Robinson Chimeric mouse human antibodies with specificity to hiv antigens
WO1991007493A1 (en) 1989-11-13 1991-05-30 Xoma Corporation Chimeric mouse human antibodies with specificity to hiv antigens
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
EP0459577A3 (en) 1990-06-01 1992-08-05 Merck & Co. Inc. Microbially expressed portions of a monoclonal antibody block rhinovirus attachment to cell receptors
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
US5223396A (en) 1991-05-03 1993-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. Method for detecting organ transplant rejection
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
EP0571613B1 (en) * 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
DE69309472T2 (de) 1992-01-23 1997-10-23 Merck Patent Gmbh, 64293 Darmstadt Fusionsproteine von monomeren und dimeren von antikörperfragmenten
US5330101A (en) 1992-02-06 1994-07-19 Nordson Corporation Material changeover and anti-skin over system
US6129914A (en) * 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
WO1993019660A1 (en) 1992-04-03 1993-10-14 Baylor College Of Medicine Gene therapy using the intestine
US6329507B1 (en) 1992-08-21 2001-12-11 The Dow Chemical Company Dimer and multimer forms of single chain polypeptides
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5674703A (en) 1992-12-02 1997-10-07 Woo; Savio L. C. Episomal vector systems and related methods
ES2156149T3 (es) * 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
US6307026B1 (en) * 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
US5491074A (en) 1993-04-01 1996-02-13 Affymax Technologies Nv Association peptides
EP0728202A4 (en) 1993-11-12 1997-04-23 Univ Case Western Reserve EPISOMIC EXPRESSION VECTOR FOR HUMAN GENE THERAPY
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
CA2117668C (en) 1994-03-09 2005-08-09 Izumu Saito Recombinant adenovirus and process for producing the same
JP3348204B2 (ja) 1994-04-20 2002-11-20 三菱アルミニウム株式会社 ろう粉末付長尺物の製造方法および装置
GB9409768D0 (en) 1994-05-16 1994-07-06 Medical Res Council Trimerising polypeptides
US5604090A (en) 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5693508A (en) 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
US5721340A (en) 1994-11-28 1998-02-24 The Wistar Institute Of Anatomy & Biology p53 proteins with altered tetramerization domains
US5573925A (en) 1994-11-28 1996-11-12 The Wistar Institute Of Anatomy And Biology P53 proteins with altered tetramerization domains
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP3770333B2 (ja) 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えｄｎａウイルスおよびその製造方法
US6110456A (en) 1995-06-07 2000-08-29 Yale University Oral delivery or adeno-associated viral vectors
WO1997005249A2 (en) 1995-07-31 1997-02-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Healt H And Human Services Extension of a protein-protein interaction surface to inactivate the function of a cellular protein
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1997023631A2 (en) * 1995-12-22 1997-07-03 Somatogen, Inc. Globins containing binding domains
EP0868521A2 (en) * 1995-12-22 1998-10-07 Somatogen Inc. Globins containing binding domains
US5861397A (en) 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
US6096291A (en) 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
DE69829995T2 (de) 1997-12-01 2006-02-23 Fang, Fang, San Diego Multivalente rekombinante antikörper zur behandlung von hrv infektionen
US20020165153A1 (en) 1998-04-06 2002-11-07 Peter Angel Transcription factors and their use
DE19815331A1 (de) * 1998-04-06 1999-10-14 Karlsruhe Forschzent Transkriptionsfaktoren und deren Verwendung
US5965712A (en) 1998-06-19 1999-10-12 Virginia Commonwealth University LZ-CD23 chimera for inhibition of IgE-mediated allergic disease
BR9915548A (pt) * 1998-10-16 2001-08-14 Biogen Inc Proteìnas de fusão de interferon-beta e usos
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
HK1044159A1 (zh) * 1998-12-01 2002-10-11 蛋白质设计实验室股份有限公司 抗γ-干扰素的人化抗体
RU2002110116A (ru) 1999-09-17 2004-03-10 Джитиси Байотерапьютикс, Инк. (Us) Гибридные белки, оптимизированные по субъединицам
CA2407426A1 (en) 2000-04-28 2001-11-08 Planet Biotechnology, Inc. Immunoadhesin for the prevention of rhinovirus infection
EP1578917A4 (en) 2001-07-19 2008-01-23 Perlan Therapeutics Inc MULTIMEDIA PROTEINS AND METHODS FOR THE PRODUCTION AND USE THEREOF
JP4236000B2 (ja) 2003-09-25 2009-03-11 元気株式会社 ３次元画像処理装置、３次元画像処理方法及びプログラム

Also Published As

Publication number Publication date
US20130243768A1 (en) 2013-09-19
US20030138440A1 (en) 2003-07-24
CA2898314A1 (en) 2003-07-31
AU2009201466A1 (en) 2009-05-07
EP1578917A4 (en) 2008-01-23
JP5264518B2 (ja) 2013-08-14
JP2013013417A (ja) 2013-01-24
AU2002365196B8 (en) 2009-01-29
WO2003062370A3 (en) 2005-12-15
AU2009201466B2 (en) 2012-05-03
JP2005522192A (ja) 2005-07-28
CA2454358A1 (en) 2003-07-31
EP1578917A2 (en) 2005-09-28
US8394771B1 (en) 2013-03-12
AU2002365196B2 (en) 2009-01-15
JP2009136292A (ja) 2009-06-25
WO2003062370A2 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
AU2009201466B2 (en) Multimeric proteins and methods of making and using same
AU2008258214B2 (en) Humanized antibodies against ICAM-1, their production and uses
AU2002365196A1 (en) Multimeric proteins and methods of making and using same
AU2002363027A1 (en) Humanized antibodies against ICAM-1, their production and uses
CN102781960B (zh) Hsa相关组合物及使用方法
EP1114161A1 (en) Immunoglobulin binding protein
AU2012207040B2 (en) Multimeric proteins and methods of making and using same
AU2013204068A1 (en) Multimeric proteins and methods of making and using same
MAHIOU et al. Soluble FasR ligand-binding domain: high-yield production of active fusion and non-fusion recombinant proteins using the baculovirus/insect cell system
HK1159139A (en) Humanized antibodies against icam-1, their production and uses
AU2013204969A1 (en) Humanized antibodies
JPWO1997042319A1 (ja) 新規Ｆａｓ抗原誘導体

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 23, NO 2, PAGE(S) 6291 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME PERLAN THERAPEUTICS, INC., APPLICATION NO. 2002365196, UNDER INID(72), CORRECT THE CO-INVENTOR NAME TO CHARLES, CATHERINE HELEN

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 27 MAR 2009.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 27 MAR 2009

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired